The Drug Enforcement Administration appears to have filed for a temporary extension of telehealth flexibilities beyond the public health emergency. This reflects an apparent reaction on the part of the DEA to the major backlash it faced during the public comment period for two rules it release that would reestablish austere restrictions on accessing treatment via telehealth that includes a controlled substance such as buprenorphine for opioid use disorder (OUD) or Adderall for ADHD. It also gives an additional cushion as the federal public health emergency (PHE) ends and pre-COVID regulations come back into play.
Read the full article: DEA Delays Ending Controlled-Substances Prescribing Flexibilities, Buys More Time for Virtual MAT Providers //
Source: https://bhbusiness.com/2023/05/02/dea-delays-ending-controlled-substances-prescribing-flexibilities-buys-more-time-for-virtual-mat-providers